Delaware HB429 amends the step therapy exception process to allow insurers to require patients to try generic or biosimilar drugs before covering.
Delaware HB429 amends Title 18 of the Delaware Code to modify the step therapy exception process. The bill allows insurers, health plans, or utilization review entities to require patients to try an AB-rated generic equivalent or an interchangeable biological product before covering the equivalent branded prescription drug. This change aims to promote the use of more cost-effective alternatives while ensuring patients have access to necessary medications.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.